The Cologuard Plus test is being offered as an in-network service to eligible Humana Medicare Advantage members.

Baron Funds, an investment management company, released its “Baron Health Care Fund” second-quarter 2025 investor letter. A ...

Exact Sciences (EXAS) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results ...

Exact Sciences Corporation (NASDAQ:EXAS) is one of the best mid cap pharma stocks to buy. On July 9, Exact Sciences announced ...

Exact Sciences is also developing blood-based tests to help in multi-cancer and MRD screening. The company has been actively engaging in M&A to support the development of these new products.

About Exact Sciences A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier.

Key Points Exact Sciences has the potential to be a big name in cancer testing and screening in the future. It already has multiple tests, and is working on one that can screen for multiple cancers.

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today the appointment of Aaron Bloomer as chief financial ...

Exact Sciences, the maker of at-home colon cancer screening test Cologuard, said it will buy Cambridge, Massachusetts-based Thrive Earlier Detection Corp. for $2.15 billion in cash and stock.

Exact Sciences plans to launch the new product in the second half of 2020. Exact Sciences thinks that it now has a total addressable market of $20 billion.

Exact Sciences is expected to maintain strong growth on top of FYE 2020 revenues of $1.49B and a 3-year expected CAGR of 20%, albeit down from 2017-2020's growth CAGR of >75%.

On March 3, 2020, Exact Sciences announced completion of its acquisition of Paradigm Diagnostics, Inc. and Viomics, Inc., privately held companies based in Phoenix, AZ. According to Exact Sciences ...